Well, isn’t that special

Specialty pharmaceutical products are doing quite well these days and many have progressed in their life cycle to the point where they are obtaining approvals for new indications. See here for a 2017 list. If you look about half way down the list you will see Sovaldi and Harvoni (both Hep C medications from Gilead). FYI, sales of these two products were ~$14B (with a B) in 2016. As the Church Lady would say, “Isn’t that special?” (Side note: it doesn’t hurt having the CDC help your marketing efforts.) There could be a trend emerging that boosts recommended testing for various conditions. By programming alerts into EMR systems, researchers found hepatitis C virus (HCV) screening rates jumped five-fold. Maybe soon we will see pharma companies helping EMR companies program alerts into their systems.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn